Long-term effects of human development on the global burden of gallbladder and biliary tract cancer: a longitudinal multilevel analysis, 1990–2021 Human Development and GBTC Burden
Gastroenterology and Hepatology from Bed to Bench,
,
2 March 2026
,
Page 1-12 (e3)
https://doi.org/10.22037/ghfbb.v19i01.3238
Abstract
Aim: To evaluate the longitudinal effect of human development on the global burden of gallbladder and biliary tract cancers (GBTC) from 1990 to 2021.
Background: GBTCs are rare but highly fatal malignancies with substantial geographic heterogeneities in incidence and mortality. Socioeconomic development, quantified through Human Development Index (HDI), may influence GBTC burden, but its long-term impact has not been quantified using longitudinal data.
Methods: This ecological study analyzed Global Burden of Disease (GBD) 2021 estimates across 204 countries. Four age-standardized indicators were examined, incidence rate (ASIR), mortality rate (ASMR), years-of-life-lost rate (ASYLLR), and mortality-to-incidence ratio (MIR). Temporal trends and HDI effects were evaluated using a longitudinal multilevel Gamma generalized linear mixed model (GLMM) to account for regional clustering and global heterogeneity.
Results: Between 1990 and 2021, all four indicators declined in both development groups, with steeper reductions in more-developed countries. The ASMR and ASYLLR were initially higher in high-HDI regions but declined more rapidly, crossing below less-developed regions in the early 2000s. MIR showed a delayed but sharper decrease, falling below 1 in more-developed settings around 2010, while remaining above 1 in less-developed areas. The longitudinal GLMM confirmed significant HDI–time interactions (p < 0.001), indicating faster burden reduction with higher development levels.
Conclusion: Human development is strongly associated with accelerated declines in GBTC incidence, mortality, and fatal burden. The results highlight the critical role of socioeconomic progress, healthcare infrastructure, and early detection in reducing disparities, underscoring the importance of targeted investments in low- and middle-HDI countries to achieve more equitable global cancer control.
- Gallbladder Neoplasms
- Bile Duct Neoplasms
- Global Burden of Disease
- Human Development
- Longitudinal Studies
- Multilevel Analysis
- Mortality
- Incidence
- Socioeconomic Factors
How to Cite
References
1. Lei S, Huang G, Li X, Xi P, Yao Z, Lin X. Global burden, trends, and inequalities of gallbladder and biliary tract cancer, 1990-2021: a decomposition and age-period-cohort analysis. Liver Int 2025;45:e16199.
2. Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol 2019;8:31.
3. Ouyang G, Liu Q, Wu Y, Liu Z, Lu W, Li S, et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017. Cancer 2021;127:2238-50.
4. Zhan Z, Chen B, Teng W, Huang R, Zheng H, Zhou S, et al. Trends and projections of gallbladder and biliary tract cancer in China: a comprehensive analysis from 1990 to 2030 based on the Global Burden of Disease Study 2021. BMC Public Health 2025;25:2409.
5. Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol 2019;5:93-102.
6. Halaseh SA, Halaseh S, Shakman R. A review of the etiology and epidemiology of gallbladder cancer: what you need to know. Cureus 2022;14:e28260.
7. Su J, Liang Y, He X. Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019. Front Med 2024;11.
8. Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2133-61.
9. Murray CJL. Findings from the Global Burden of Disease Study 2021. Lancet 2024;403:2259-62.
10. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2100-32.
11. de Siqueira JH, Mtewa AG, Fabriz DC. United Nations Development Programme (UNDP). In: Sayapin S, Atadjanov R, Kadam U, Kemp G, Zambrana-Tévar N, Quénivet N, eds. International Conflict and Security Law: A Research Handbook. The Hague, Netherlands, L.T.M.C. Asser Press The Hague; 2022. p. 761-77.
12. Zhu K-F, Wang Y-M, Zhu J-Z, Zhou Q-Y, Wang N-F. National prevalence of coronary heart disease and its relationship with human development index: a systematic review. Eur J Prev Cardiol 2016;23:530-43.
13. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 2012;13:790-801.
14. Brooks ME, Kristensen K, Van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. The R Journal 2017.
15. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw 2015;67:1-48.
16. Theall KP, Scribner R, Broyles S, Yu Q, Chotalia J, Simonsen N, et al. Impact of small group size on neighbourhood influences in multilevel models. J Epidemiol Community Health 2011;65:688-95.
17. Dai F, Luo H, Cai Y, Dai Y. Global burden, temporal trends, and health workforce correlations of gallbladder and biliary tract cancer: a comprehensive analysis from 1990 to 2021 with projections to 2046. BMC Gastroenterol 2025;25:596.
18. Xie D, Liu F, Zhou D, Zhu Q, Xiao F, Zhang K. Global burden and cross-country inequalities in gallbladder and biliary tract cancer (1990-2021) with projections to 2050: insights from the global burden of disease study 2021. Front Med 2025;12:1520714.
19. Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014;39:745-50.
20. Diehl A, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet 1981;318:187-9.
21. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100B. Lyon (FR): International Agency for Research on Cancer; 2012.
22. Prueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. Liver fluke-associated biliary tract cancer. Gut Liver 2018;12:236-45.
23. Xiao YX, Chen J, Li ZY, Zou YX, Zhou XH, Zhang W, et al. Global trends in gallbladder cancer survival: A 30-year analysis of cancer registry data. Heliyon 2025;11:e42853.
24. Martinez R, Soliz P, Caixeta R, Ordunez P. Reflection on modern methods: years of life lost due to premature mortality—a versatile and comprehensive measure for monitoring non-communicable disease mortality. Int J Epidemiol 2019;48:1367-76.
25. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-48.
26. Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 2022;8:420-44.
27. Ellis L, Belot A, Rachet B, Coleman MP. The mortality-to-incidence ratio is not a valid proxy for cancer survival. J Glob Oncol 2019;5:1-9.
28. Koshiol J, Wozniak A, Cook P, Adaniel C, Acevedo J, Azócar L, et al. Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. Cancer Med 2016;5:3310-235.
29. Di Le M, Henson D, Young H, Albores-Saavedra J. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol 2016;10:306-14.
30. Li M, Li J, Li S, Zhang M, Li S, Zhao J, et al. Global, regional, and national burden of gallbladder and biliary tract cancer among adults aged 55 years and older, 2010–2021. Front Nutr 2025;12.
31. Azizmohammad Looha M, Saberi Shahrbabaki A, Mohammadpoor A, Zamani M, Sadeghloo Z, Jameie M, et al. Global and regional trends in under-five diarrheal disease burden: impact of human development index and geographic disparities, 1990-2021. Gastroenterol Hepatol Bed Bench 2025;18:177-95.
32. Masaebi F, Farahmandkia Z, Azizmohammad Looha M, Asadimanesh N, Mohebbi H, Mehrasbi MR. Global burden, trends, and projections of self-harm and interpersonal violence: 1990-2040. J Hum Environ Health Promot 2026;12:36.
33. Azizmohammad Looha M, Saberi Shahrbabaki A, Zamani M, Zareie Shab Khaneh A, Javadi S, Sadeghloo Z, et al. Burden of pancreatic cancer in Iran: an analysis of Global Burden of Disease 2021. Gastroenterol Hepatol Bed Bench 2025;18:455-466.
34. Azizmohammad Looha M, Saberi Shahrbabaki A, Yoosefi S, Javadi S, Pourhoseingholi MA, Moradi A. Association between the human development index and the burden of major gastrointestinal cancers: trends and spatial patterns of alcohol-related cirrhosis mortality. Gastroenterol Hepatol Bed Bench 2025;18:467-482.
- Abstract Viewed: 280 times
- PDF Downloaded: 188 times